Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

7.039 -0.131 (-1.83%)
Streaming Delayed Price Updated: 1:17 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
News headline image
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
News headline image
Recap: Certara Q3 Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Certara ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Certara ↗
 
Via Benzinga
News headline image
Looking Into Certara's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Certara Reports Third Quarter 2023 Financial Results
Reiterates Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
News headline image
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines 
From Certara
Via GlobeNewswire
News headline image
Analyst Expectations for Certara's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Certara ↗
 
Via Benzinga
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations 
From Certara
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Certara Reports Second Quarter 2023 Financial Results
Provides Update to Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Certara Reports First Quarter 2023 Financial Results
Reiterates 2023 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients 
From Certara
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023 ↗
 
Via Benzinga
News headline image
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗
 
Via Benzinga
News headline image
Are These 3 Small Momentum Stocks Setting Up Big Gains?
MINISO, PDF Solutions, and Certara are small stocks with strong price momentum. It’s not unusual for small stocks to show more price momentum than larger peers. 
Via MarketBeat
News headline image
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy... 
Via Benzinga
News headline image
Signet Jewelers, Designer Brands, Academy Sports and Outdoors And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones dropping more than 250 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
A.I. Coming to Certara’s D360 Scientific Informatics Software
New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. 
From Certara
Via GlobeNewswire
News headline image
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies 
From Certara
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.